CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL

NCT05716113 EARLY_PHASE1 COMPLETED

This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL, and to evaluate the pharmacokinetics of CD7 CAR-T in patients.

Details

Lead sponsor	He Huang
Phase	EARLY_PHASE1
Status	COMPLETED
Enrolment	20
Start date	Thu Feb 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Aug 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Neoplasms
• Hematologic Neoplasms
• Neoplasms by Site
• Hematologic Diseases

Interventions

• RD13-02 cell infusion

Countries

China